Trial reportNature communications2017
MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes.
Trial report in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05017311 (Optimized Predictive Treatment In Medications for Unipolar Major Depression), which is not on this map. Cited by 118 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Who cites it
118 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- MicroRNAs and suicidality: a systematic review and bioinformatic evaluation.Frontiers in psychiatry · 2026Pooled it
- Recent developments in omics studies and artificial intelligence in depression and suicide.Translational psychiatry · 2025Pooled it
- miRNAs in treatment-resistant depression: a systematic review.Molecular biology reports · 2024Pooled it
- Transcriptomic Studies of Antidepressant Action in Rodent Models of Depression: A First Meta-Analysis.International journal of molecular sciences · 2022Pooled it
- Changes in RNA expression levels during antidepressant treatment: a systematic review.Journal of neural transmission (Vienna, Austria : 1996) · 2021Pooled it
- Identification of antidepressant response-related changes to DNA methylation and gene expression.The international journal of neuropsychopharmacology · 2026Trial
- Changes in Multiple microRNA Levels with Antidepressant Treatment Are Associated with Remission and Interact with Key Pathways: A Comprehensive microRNA Analysis.International journal of molecular sciences · 2023Trial
- Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways.International journal of molecular sciences · 2022Trial
- Trial
- Exercise - induced changes in cerebrospinal fluid miRNAs in Gulf War Illness, Chronic Fatigue Syndrome and sedentary control subjects.Scientific reports · 2017Trial
- Longitudinal Analysis of Peripheral MicroRNA Expression and Depressive Symptom Severity Change in a Community Cohort.Epigenomes · 2026Article
- Transcriptional profiles of antidepressant resistance across the corticolimbic pathway of chronically stressed mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- MIR1255A regulates pathways critical for brain development, risk genes for depression and neurodevelopmental disorders.Translational psychiatry · 2026Article
- Article
- Neuroplacentology of stress: Novel frontiers linking maternal mental health to offspring neurodevelopment.Neurobiology of stress · 2026Review
- MicroRNA-425-3p: A Promising Biomarker and Candidate for Pharmacological Intervention in Neuropsychiatric Disabilities with Relevance to Major Depressive Disorder.Neuropsychiatric disease and treatment · 2026Review
- Neurobiology of resilience to early life stress.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Extracellular vesicle microRNAs are biomarkers of focal epilepsy but not epilepsy-related respiratory dysfunction.Epilepsia · 2026Article
- Distinct genetic responses to fluoxetine sertraline and citalopram in mouse cortical neurons.iScience · 2025Article
- Nanotechnology-Enhanced MicroRNAs for Improved Diagnosis and Treatment of Major Depressive Disorder: A Comprehensive Review.Molecular neurobiology · 2025Review
58 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Funding
Abstract
Antidepressants (ADs) are the most common treatment for major depressive disorder (MDD). However, only ∼30% of patients experience adequate response after a single AD trial, and this variability remains poorly understood. Here, we investigated microRNAs (miRNAs) as biomarkers of AD response using small RNA-sequencing in paired samples from MDD patients enrolled in a large, randomized placebo-controlled trial of duloxetine collected before and 8 weeks after treatment. Our results revealed differential expression of miR-146a-5p, miR-146b-5p, miR-425-3p and miR-24-3p according to treatment response. These results were replicated in two independent clinical trials of MDD, a well-characterized animal model of depression, and post-mortem human brains. Furthermore, using a combination of bioinformatics, mRNA studies and functional in vitro experiments, we showed significant dysregulation of genes involved in MAPK/Wnt signalling pathways. Together, our results indicate that these miRNAs are consistent markers of treatment response and regulators of the MAPK/Wnt systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.